2026 Interim Report
Filed with HKEX · Stock code 314 · · 78 pages · English and Chinese
Summary by 6ix AI
The report highlights a significant turnaround to profitability, with the company achieving a net profit compared to a loss in the same period last year. Additionally, the report discusses the company's focus on enhancing its core business areas and improving operational efficiency. The financial summary indicates a decrease in total revenue, primarily due to strategic reductions in certain business segments, while core services showed growth.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Sipai Health Technology Co., Ltd. on 6ix
Earlier from Sipai Health Technology
- Sipai Health Technology's Unit Disposes 100% Stake In Sipai Zhihe Technology (Guangzhou) Co
- Sipai Health Technology Says Bixun Pharmaceutical To Buy Shanze Technology
- Sipai Health Technology Expects Normalized Net Loss Of No More Than RMB50 MLN For FY
Later from Sipai Health Technology
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Major transaction disposal of 100% equity interest in the target company
- Voluntary announcement acquisition of a 90% indirect equity interest in a licensed insurance broker company
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
- Further announcement on major transaction disposal of 100% equity interest in the target company and delay in despatch of circular
Follow Sipai Health Technology into a list and get an email when it puts out news.
Follow Sipai Health Technology